9IP1 Stock Overview
Operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Rocket Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$13.05 |
| 52 Week High | US$29.42 |
| 52 Week Low | US$11.71 |
| Beta | 1.09 |
| 11 Month Change | -19.05% |
| 3 Month Change | -21.93% |
| 1 Year Change | -36.02% |
| 33 Year Change | -38.47% |
| 5 Year Change | -21.42% |
| Change since IPO | 36.53% |
Recent News & Updates
Recent updates
Shareholder Returns
| 9IP1 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 8.1% | -1.1% | 1.1% |
| 1Y | -36.0% | -18.8% | 7.2% |
Return vs Industry: 9IP1 underperformed the German Biotechs industry which returned -18.3% over the past year.
Return vs Market: 9IP1 underperformed the German Market which returned 8.6% over the past year.
Price Volatility
| 9IP1 volatility | |
|---|---|
| 9IP1 Average Weekly Movement | 11.5% |
| Biotechs Industry Average Movement | 6.6% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 9IP1's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 9IP1's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 268 | Gaurav Shah | www.rocketpharma.com |
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy, an inheritable cardiac disorder; and BAG3 Dilated Cardiomyopathy.
Rocket Pharmaceuticals, Inc. Fundamentals Summary
| 9IP1 fundamental statistics | |
|---|---|
| Market cap | €1.22b |
| Earnings (TTM) | -€244.27m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-5.0x
P/E RatioIs 9IP1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 9IP1 income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$258.08m |
| Earnings | -US$258.08m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.83 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 9IP1 perform over the long term?
See historical performance and comparison